ISAL 2019 | Pre/post allo-SCT checkpoint inhibitors: a double-edged sword

Naval Daver

The double-edged sword of checkpoint inhibitors used before or after allogeneic hematopoietic stem cell transplant is discussed here by Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video  
Similar topics